A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019

被引：11
|
作者：
Shabani, M. [1 ]
Ehdaei, B. Sadegh [2 ]
Fathi, F. [3 ]
Dowran, R. [1 ]
机构：
[1] Univ Tehran Med Sci, Sch Publ Hlth, Dept Virol, Tehran, Iran
[2] Kashan Univ Med Sci, Fac Med, Microbiol & Immunol Dept, Kashan, Iran
[3] Isfahan Univ Med Sci, Sch Med, Dept Immunol, Esfahan, Iran
来源：
NEW MICROBES AND NEW INFECTIONS | 2021年 / 42卷
关键词：
COVID-19; daclatasvir; HCV; SARS-CoV-2; sofosbuvir; HEPATITIS-C VIRUS; HCV GENOTYPE 1; PLUS SOFOSBUVIR; LIVER-TRANSPLANTATION; VIRAL-HEPATITIS; INFECTION; EPIDEMIOLOGY; RESISTANCE; INHIBITOR; EFFICACY;
D O I：
10.1016/j.nmni.2021.100895
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between hepatitis C virus RNA polymerase and severe acute respiratory syndrome coronavirus 2 has also been established. The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized. (c) 2021 The Authors. Published by Elsevier Ltd.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Acupuncture Treatment for Coronavirus Disease 2019: A Review Article
    Nurwati, Ida
    Huda, Khairunnisa Nurul
    MEDICAL ACUPUNCTURE, 2021, 33 (01) : 45 - 48
  • [22] Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late
    Pellicelli, Adriano M.
    Montalbano, Marzia
    Lionetti, Raffaella
    Durand, Christine
    Ferenci, Peter
    D'Offizi, Gianpiero
    Knop, Viola
    Telese, Andrea
    Lenci, Ilaria
    Andreoli, Arnaldo
    Zeuzem, Stefan
    Angelico, Mario
    DIGESTIVE AND LIVER DISEASE, 2014, 46 (10) : 923 - 927
  • [23] Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure
    Mohamed, Hala
    Abd El Ghany, Weal
    Yehia, Reem
    Fouad, Magdy
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 8 (01) : 36 - 41
  • [24] Piezoelectric Biosensors and Nanomaterials-based Therapeutics for Coronavirus and Other Viruses: A Mini-review
    Ramasamy, Madeshwaran Sekkarapatti
    Bhaskar, Rakesh
    Han, Sung Soo
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2023, 23 (02) : 115 - 127
  • [25] Efficacy of Sofosbuvir and Daclatasvir in the Treatment of Chronic Hepatits Viral Infection
    Arif, Mohammad
    Zaman, Shah
    Khan, Amir Zaman
    Nasim, Riaz
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (12): : 3164 - 3166
  • [26] Stroke in Coronavirus Disease 2019: A Systematic Review
    Bhatia, Rohit
    Pedapati, Radhakrishna
    Komakula, Snigdha
    Srivastava, Mv Padma
    Vishnubhatla, Sreenivas
    Khuranac, Dheeraj
    JOURNAL OF STROKE, 2020, 22 (03) : 324 - +
  • [27] Coronavirus disease 2019 and the placenta: A literature review
    Gesaka, Samwel R.
    Obimbo, Moses M.
    Wanyoro, Anthony
    PLACENTA, 2022, 126 : 209 - 223
  • [28] Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review
    Lu, Ling-Ying
    Feng, Po-Hao
    Yu, Ming-Sun
    Chen, Min-Chi L.
    Lin, Alex Jia-Hong
    Chen, Justin L.
    Yu, Lennex Hsueh-Lin
    CYTOKINE & GROWTH FACTOR REVIEWS, 2022, 63 : 34 - 43
  • [29] Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
    Sperl, Jan
    Frankova, Sona
    Kreidlova, Miluse
    Merta, Dusan
    Tothova, Monika
    Spicak, Julius
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 733 - 738
  • [30] Essential Oils for Treatment for Onychomycosis: A Mini-Review
    Flores, Fernanda C.
    Beck, Ruy C. R.
    da Silva, Cristiane de B.
    MYCOPATHOLOGIA, 2016, 181 (1-2) : 9 - 15
12345